Overview of bladder cancer trials in the Radiation Therapy Oncology Group
- 1 April 2003
- Vol. 97 (S8), 2115-2119
- https://doi.org/10.1002/cncr.11282
Abstract
In the United States, radical cystectomy is viewed as the gold standard and, with few exceptions, is the only treatment recommended for patients with invasive bladder cancer. In many areas of cancer treatment, however, the trend in the 1990s has been toward organ conservation using combined chemotherapy and radiation with or without conservative local surgery. For patients with breast, esophageal, anal, and laryngeal cancers as well as limb sarcomas, conservative therapy often is recommended. However, invasive bladder cancer has not been viewed generally as a condition that allows for conservative management. In the past 15 years, the Radiation Therapy Oncology Group (RTOG) has completed six prospective protocols of combined-modality therapy for patients with muscle-invasive cancer who were candidates for cystectomy. Bladder preservation with intravesical surgery, chemotherapy, and radiation therapy were combined as initial treatment, with radical cystectomy recommended for incomplete responders. Five of the RTOG protocols were Phase I-II trials of concurrent chemotherapy and radiation therapy, and one protocol was a Phase III trial that tested the efficacy of adjuvant chemotherapy with methotrexate, cisplatin, and vinblastine. A total of 415 patients were entered on these trials. The 5-year overall survival rate was approximately 50%, with three-quarters of those patients achieving a cure for their bladder cancer while maintaining a functioning bladder. The current RTOG protocol and its successor are directed toward better tolerated and potentially more effective chemotherapy regimens that may result in a high protocol compliance rate and, possibly, a higher overall survival rate. The trimodality therapeutic approach used in all of these RTOG protocols was more effective compared with the radiation monotherapy offered in the 1970s and with protocols that used only chemotherapy. Trimodality therapy with selective bladder preservation is not designed to take the place of radical cystectomy; however, it may be offered as a reasonable alternative to patients with invasive bladder cancer who are not willing to undergo radical cystectomy and urinary diversion. A bladder-sparing strategy may be offered appropriately to highly selected patients with the understanding that radical cystectomy is an available option in those who fail combined radiation and chemotherapy with no diminution in survival related to the delay in cystectomy.Keywords
This publication has 13 references indexed in Scilit:
- RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- COMBINATION CISPLATIN, 5-FLUOROURACIL AND RADIATION THERAPY FOR LOCALLY ADVANCED UNRESECTABLE OR MEDICALLY UNFIT BLADDER CANCER CASES: A SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2001
- The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial ResponseThe Oncologist, 2000
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial CancerJournal of Clinical Oncology, 2000
- Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2000
- Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomyAnnals of Medicine, 2000
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialThe Lancet, 1999
- Selective Bladder Preservation by Combination Treatment of Invasive Bladder CancerThe New England Journal of Medicine, 1993
- Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12International Journal of Radiation Oncology*Biology*Physics, 1993